a public good project by the
Synthesis
Company
of California

© 2026

Haoyu Pan | doi.page

0 works0 citations0 h-index

Haoyu Pan

Zhejiang Chinese Medical University(CN)Sir Run Run Shaw Hospital(CN)Zhejiang Cancer Hospital(CN)Zhejiang Lab(CN)Center for Special Minimally Invasive and Robotic Surgery(US)Zhejiang University(CN)

Publications by Year

Research Areas

MicroRNA in disease regulation, Hepatocellular Carcinoma Treatment and Prognosis, Ferroptosis and cancer prognosis, Cholangiocarcinoma and Gallbladder Cancer Studies, Circular RNAs in diseases

Most-Cited Works

→ Circ-RAPGEF5 promotes intrahepatic cholangiocarcinoma progression by stabilizing SAE1 to facilitate SUMOylation(2023)29 cited
→ Synergistic Anticancer Strategy Targeting ECM Stiffness: Integration of Matrix Softening and Mechanical Signal Transduction Blockade in Primary Liver Cancers(2024)16 cited
→ Noninvasive prognostic classification of ITH in HCC with multi-omics insights and therapeutic implications(2025)11 cited
→ Exploration of a screening model for intrahepatic cholangiocarcinoma patients prone to cuproptosis and mechanisms of the susceptibility of CD274-knockdown intrahepatic cholangiocarcinoma cells to cuproptosis(2023)9 cited
→ A Novel MPT ‐Driven Necrosis‐Related lncRNA Signature for Prognostic Prediction in Hepatocellular Carcinoma: Validation Using Organoids(2025)1 cited
→ Additional file 1 of Circ-RAPGEF5 promotes intrahepatic cholangiocarcinoma progression by stabilizing SAE1 to facilitate SUMOylation

(2023)

→ Robotic versus laparoscopic liver resection for the treatment of hepatocellular carcinoma: an observational study(2023)

→ Research on the Application of Virtual Simulation Technology in the Teaching of Programmable Application Technology(2024)

→ Targeting LDL Dysregulation for Intrahepatic Cholangiocarcinoma Prevention: Clinical and Translational Evidence from Lipid-Lowering Drug Mendelian Randomization(2025)